Anthera Pharmaceuticals Inc (NASDAQ:ANTH) announced on Thursday that net loss in fiscal fourth-quarter was $8.9 million or $0.11 a share, narrower than $29.2 million or $0.71 a share in the similar period a year ago.
Thomson Reuters 7 analysts’ survey on average forecasted to announce a loss of $0.16 a share for three months period.
The company reported that loss from operations narrowed from $28.2 million to $8.1 million in the similar quarter a year ago.
Total operating costs for most recent period fell to $8.1 million from $28.4 million in the similar period previous year.
Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Eli Lilly & Co. (NYSE:LLY) rose +1.20% to settle at $56.29, Merck & Co., Inc. (NYSE:MRK) moved up +1.60% to end at $44.39 while Immunomedics, Inc. (NASDAQ:IMMU) jumped +1.24% to finish at $2.44 on Tuesday.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) last session’s volume of 484,007 shares was lower than its average volume of 993,314 shares. The stock after opening at $0.65 hit high price of $0.66 and then closed at $0.650 by scoring +1.56%.
The ANTH’s past twelve months’ price to cash ratio was 0.50. As far as the returns are concerned, ANTH’s return on equity was recorded as -300.12% and return on investment decreased -175.45% while its return on asset stayed at -113.80%.
The stock showed weekly upbeat performance of 1.56% which was maintained for the month at 4.84%. Likewise the positive performance for the quarter was recorded as 1.56% and for the year was -73.90% while the YTD performance remained at 4.84%.
DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL